TN-301

About Tenaya Therapeutics

Tenaya Therapeutics is a biotechnology company founded by leading cardiovascular scientists with a mission to discover, design, develop, and deliver potentially curative therapies for heart disease. The company's core focus is on its clinical-stage gene therapy programs targeting specific genetic cardiomyopathies, with promising data reported in 2025 and key regulatory and data milestones planned for 2026. Beyond gene therapy, Tenaya is also developing TN-301, a highly selective HDAC6 inhibitor, for conditions like Duchenne muscular dystrophy, and has entered a research collaboration with Alnylam Pharmaceuticals to identify novel cardiovascular disease targets.

Therapeutic Areas